Business Description
Sionna Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US8294011080
Total Employee Number:
59Description
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 26.15 | |||||
Equity-to-Asset | 0.94 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 2.4 | |||||
3-Year EPS without NRI Growth Rate | 6.8 | |||||
3-Year FCF Growth Rate | 8.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -15.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 13.33 | |||||
9-Day RSI | 17.34 | |||||
14-Day RSI | 21.51 | |||||
3-1 Month Momentum % | 22.85 | |||||
6-1 Month Momentum % | 29.92 | |||||
12-1 Month Momentum % | 137.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 20.05 | |||||
Quick Ratio | 20.05 | |||||
Cash Ratio | 19.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 0.41 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -32.06 | |||||
ROA % | -30.33 | |||||
ROIC % | -127.71 | |||||
3-Year ROIIC % | -55.97 | |||||
ROC (Joel Greenblatt) % | -1211.34 | |||||
ROCE % | -35.18 | |||||
Moat Score | 1 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.97 | |||||
Price-to-Tangible-Book | 0.97 | |||||
EV-to-EBIT | -0.49 | |||||
EV-to-EBITDA | -0.5 | |||||
EV-to-Forward-Revenue | 53.22 | |||||
EV-to-FCF | -0.71 | |||||
| Price-to-Net-Current-Asset-Value | 1.29 | |||||
| Price-to-Net-Cash | 1.33 | |||||
Earnings Yield (Greenblatt) % | -204.08 | |||||
FCF Yield % | -29.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SION
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sionna Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.18 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 56.79 | ||
| 14-Day RSI | 21.51 | ||
| 14-Day ATR ($) | 4.899912 | ||
| 20-Day SMA ($) | 34.73 | ||
| 12-1 Month Momentum % | 137.32 | ||
| 52-Week Range ($) | 4.01 - 54.97 | ||
| Shares Outstanding (Mil) | 45.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sionna Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sionna Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 79 days | ||
| Sionna\'s Topline Data Presentation for SION-719 Phase 2a and SION-451 Dual Combination Phase 1 | 2026-08-10 08:00 | 51.04 (+0.35%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 47.34 (-5.70%) | ||
| General meeting for 2026 | 2026-06-17 12:00 | 34.75 (-3.47%) | ||
| Goldman Sachs 47th Annual Global Healthcare Conference | 2026-06-10 10:00 | 33.69 (-1.98%) | ||
| Guidance call for 2026 | 2026-06-03 12:15 | 36.48 (-9.30%) | ||
| RBC Capital Markets Global Healthcare Conference | 2026-05-20 14:05 | 37.68 (-1.26%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 45.95 (+2.84%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 13:40 | 37.53 (+5.48%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-02 14:30 | 36.54 (-1.91%) |
Show
Entries
Sionna Therapeutics Inc Frequently Asked Questions
What is Sionna Therapeutics Inc(SION)'s stock price today?
The current price of SION is $5.69. The 52 week high of SION is $54.97 and 52 week low is $4.01.
When is next earnings date of Sionna Therapeutics Inc(SION)?
The next earnings date of Sionna Therapeutics Inc(SION) is 2026-11-05 Est..
Does Sionna Therapeutics Inc(SION) pay dividends? If so, how much?
Sionna Therapeutics Inc(SION) does not pay dividend.
Guru Commentaries on NAS:SION
No articles.
Press Release
Articles on Sionna Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers